[Clinical studies of the therapeutic effect of Flucinom in prostatic cancer]

Experience is recorded in the treatment of prostate cancer with Flucinom in 42 patients at mean age 64 years. This is a new synthetic patent medicine, a nonsteroid antiandrogen, product of the firm Schering (USA). It acts as concurrent inhibitor of the androgen acceptors in the cytoplasm of the glandular epithelium in prostate cells and averts the entry of the androgenic acceptor complex in the nucleus. Treatment was conducted with Flucinom tablets of 250 mg, 3 times daily 1 tablet. Patients in different stages of the disease were treated. The results were recorded for each patient individually at mean duration of the follow-up period 16 months. Twenty-eight patients received only Flucinom medication, in 14 drug treatment was combined with pulpectomy. The effect of treatment was as follows: regression--26 patients (61.9 per cent, stabilization--10 patients (23.8 per cent) and progression--6 patients (14.3 per cent). The results were superior when drug treatment was associated with pulpectomy. Treatment was well tolerated, including in patients with accompanying cardiovascular diseases and initial renal failure. Side reactions were seldom observed and were mild. It is recommended that Flucinom treatment of prostate cancer should gain acceptance, especially in patients with preserved potency.